Lundbeck, a neuroscience drug developer, is acquiring Longboard Pharmaceuticals for $2.6 billion to expand its focus to epilepsy. Longboard’s lead asset is bexicaserin, a drug in late-stage development for rare seizure disorders. Bexicaserin targets the 5-HT2C receptor to regulate seizure severity, with promising results in reducing seizures. The acquisition aligns with Lundbeck’s strategy to address rare neurological diseases and projections estimate peak sales of $1.5 to $2 billion. The deal, pending shareholder and regulatory approval, is expected to close by the end of the year. Lundbeck aims to launch bexicaserin by the fourth quarter of 2028 to meet the unmet needs of epilepsy patients.
Source link
Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
